Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- step label "contrast image by factor" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- out1 label "out1" assertion.
- ratio label "ratio" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- img label "img" assertion.
- step label "Make white background of image transparent" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- step label "Add blur to image" assertion.
- plan label "puts an image infront of a second image" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- step label "awesome smoothening of an image" assertion.
- plan label "flip and smooth an image" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- ReferredMentioning label "identifier of a thing mentioned in the object that is reviewed" assertion.
- comment label "This comment" assertion.
- PositivityClass label "specify whether it is positive, neutral, or negative" assertion.
- ActionClass label "specify whether an action is required" assertion.
- ActionClass label "specify whether it is about syntax, style, or content" assertion.
- reviewComment label "The content of this comment as free text" assertion.
- impact label "integer value from 1 (low impact) to 5 (high impact)" assertion.
- ReferredObject label "identifier of the object that is reviewed (e.g. a text or nanopublication)" assertion.
- assertion label "Making a review comment according to the LinkFlows model" assertion.
- img label "img" assertion.
- step label "Convert the RGB color image to grayscale" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- step label "Apply a Gaussian blur to the negative from step 2" assertion.
- LinguisticSystem label "python" assertion.
- img label "img" assertion.
- out1 label "out1" assertion.
- factor label "factor" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- step label "Adjust the constrast of the final image" assertion.
- img label "img" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- association label "fosphenytoin sodium injection usp is indicated for the treatment of generalized tonic clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery fosphenytoin sodium injection usp can also be substituted short term for oral phenytoin fosphenytoin sodium injection usp should be used only when oral phenytoin administration is not possible see dosage and administration 2 4 precautions 5 2 fosphenytoin sodium injection usp is indicated for the treatment of generalized tonic clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery fosphenytoin sodium injection usp can also be substituted as short term use for oral phenytoin fosphenytoin sodium injection usp should be used only when oral phenytoin administration is not possible 1" assertion.
- association label "matzim la diltiazem hydrochloride extended release tablets are a nondihydropyridine calcium channel blocker indicated for treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions it can be used alone or in combination with other antihypertensives 1 1 improving exercise tolerance in patients with chronic stable angina 1 2 matzim la diltiazem hydrochloride extended release tablets are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy matzim la diltiazem hydrochloride extended release tablets may be used alone or in combination with other antihypertensive medications matzim la diltiazem hydrochloride extended release tablets are indicated to improve exercise tolerance in patients with chronic stable angina" assertion.
- association label "modafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy obstructive sleep apnea and shift work disorder in osa modafinil tablets are indicated as an adjunct to standard treatment s for the underlying obstruction if continuous positive airway pressure cpap is the treatment of choice for a patient a maximal effort to treat with cpap for an adequate period of time should be made prior to initiating modafinil tablets if modafinil tablets are used adjunctively with cpap the encouragement of and periodic assessment of cpap compliance is necessary in all cases careful attention to the diagnosis and treatment of the underlying sleep disorder s is of utmost importance prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness the effectiveness of modafinil in long term use greater than 9 weeks in narcolepsy clinical trials and 12 weeks in osa and swd clinical trials has not been systematically evaluated in placebo controlled trials the physician who elects to prescribe modafinil tablets for an extended time in patients with narcolepsy osa or swd should periodically reevaluate long term usefulness for the individual patient" assertion.
- association label "leflunomide is indicated in adults for the treatment of active rheumatoid arthritis ra to reduce signs and symptoms to inhibit structural damage as evidenced by x ray erosions and joint space narrowing to improve physical function see clinical studies aspirin nonsteroidal anti inflammatory agents and or low dose corticosteroids may be continued during treatment with leflunomide see precautions drug interactions nsaids warnings immunosuppression potential bone marrow suppression" assertion.
- association label "a intravenous or intramuscular administration when oral therapy is not feasible and the strength dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition those products labeled for intravenous or intramuscular use are indicated as follows 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance acute adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice mineralocorticoid supplementation may be necessary particularly when synthetic analogs are used preoperatively and in the event of serious trauma or illness in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2 rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in post traumatic osteoarthritis synovitis of osteoarthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy acute and subacute bursitis epicondylitis acute nonspecific tenosynovitis acute gouty arthritis psoriatic arthritis ankylosing spondylitis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus acute rheumatic carditis 4 dermatologic diseases pemphigus severe erythema multiforme stevens johnson syndrome exfoliative dermatitis bullous dermatitis herpetiformis severe seborrheic dermatitis severe psoriasis mycosis fungoides 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in bronchial asthma contact dermatitis atopic dermatitis serum sickness seasonal or perennial allergic rhinitis drug hypersensitivity reactions urticarial transfusion reactions acute noninfectious laryngeal edema epinephrine is the drug of first choice 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye such as herpes zoster ophthalmicus iritis iridocyclitis chorioretinitis diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia anterior segment inflammation allergic conjunctivitis allergic corneal marginal ulcers keratitis 7 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis systemic therapy regional enteritis systemic therapy 8 respiratory diseases symptomatic sarcoidosis berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti tuberculosis chemotherapy loeffler s syndrome not manageable by other means aspiration pneumonitis 9 hematologic disorders acquired autoimmune hemolytic anemia idiopathic thrombocytopenic purpura in adults i v only i m administration is contraindicated secondary thrombocytopenia in adults erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia 1 neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemic of childhood 11 edematous states to induce diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti tuberculosis chemotherapy trichinosis with neurologic or myocardial involvement diagnostic testing of adrenocortical hyperfunction cerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management b intra articular or soft tissue administration when the strength and dosage form of the drug lend the preparation to the treatment of the condition those products labeled for intra articular or soft tissue administration are indicated as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in synovitis of osteoarthritis rheumatoid arthritis acute and subacute bursitis acute gouty arthritis epicondylitis acute nonspecific tenosynovitis post traumatic osteoarthritis c intralesional administration when the strength and dosage form of the drug lend the preparation to the treatment of the condition those products labeled for intralesional administration are indicated for keloids localized hypertrophic infiltrated inflammatory lesions of lichen planus psoriatic plaques granuloma annulare and lichen simplex chronicus neurodermatitis discoid lupus erythematosus necrobiosis lipoidica diabeticorum alopecia areata they also may be useful in cystic tumors of an aponeurosis tendon ganglia" assertion.
- association label "cystadane is a methylating agent indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels included within the category of homocystinuria are 1 cystathionine beta synthase cbs deficiency 5 1 methylenetetrahydrofolate reductase mthfr deficiency cobalamin cofactor metabolism cbl defect cystadane r betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels included within the category of homocystinuria are cystathionine beta synthase cbs deficiency 5 1 methylenetetrahydrofolate reductase mthfr deficiency cobalamin cofactor metabolism cbl defect" assertion.
- association label "probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis as an adjuvant to therapy with penicillin or with ampicillin methicillin oxacillin cloxacillin or nafcillin for elevation and prolongation of plasma levels by whatever route the antibiotic is given" assertion.
- association label "erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen 1 1 first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with gemcitabine 1 2 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations 1 1 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy 1 1 erlotinib tablets are indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen see clinical studies 14 1 14 3 safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations see clinical studies 14 1 14 2 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy see clinical studies 14 4 erlotinib tablets in combination with gemcitabine is indicated for the first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer see clinical studies 14 5" assertion.
- association label "altabax r 2 staphylococcus aureus streptococcus pyogenes see clinical studies 14 to reduce the development of drug resistant bacteria and maintain the effectiveness of altabax and other antibacterial drugs altabax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria altabax a pleuromutilin antibacterial is indicated for the topical treatment of impetigo due to staphylococcus aureus streptococcus pyogenes 1" assertion.
- association label "prednisone tablets are indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2 rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis 4 dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis bronchial asthma contact dermatitis atopic dermatitis serum sickness drug hypersensitivity reactions 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia allergic conjunctivitis keratitis chorioretinitis optic neuritis iritis and iridocyclitis 7 respiratory diseases symptomatic sarcoidosis loeffler s syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemia of childhood 1 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement" assertion.
- association label "heparin sodium injection is indicated for prophylaxis and treatment of venous thrombosis and pulmonary embolism prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who for other reasons are at risk of developing thromboembolic disease atrial fibrillation with embolization treatment of acute and chronic consumptive coagulopathies disseminated intravascular coagulation prevention of clotting in arterial and cardiac surgery prophylaxis and treatment of peripheral arterial embolism anticoagulant use in blood transfusions extracorporeal circulation and dialysis procedures heparin sodium injection is an anticoagulant indicated for 1 prophylaxis and treatment of venous thrombosis and pulmonary embolism prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who for other reasons are at risk of developing thromboembolic disease atrial fibrillation with embolization treatment of acute and chronic consumptive coagulopathies disseminated intravascular coagulation prevention of clotting in arterial and cardiac surgery prophylaxis and treatment of peripheral arterial embolism use as an anticoagulant in blood transfusions extracorporeal circulation and dialysis procedures" assertion.
- association label "hydrocortisone tablets usp are indicated in the following conditions endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post traumatic osteoarthritis synovitis of osteoarthritis epicondylitis collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia respiratory diseases symptomatic sarcoidosis loeffler s syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemia of childhood edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis nervous system acute exacerbations of multiple sclerosis miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement" assertion.
- association label "famciclovir tablets a prodrug of penciclovir is a nucleoside analog dna polymerase inhibitor indicated for immunocompetent adult patients 1 1 herpes labialis cold sores treatment of recurrent episodes genital herpes treatment of recurrent episodes suppressive therapy of recurrent episodes herpes zoster shingles hiv infected adult patients 1 2 treatment of recurrent episodes of orolabial or genital herpes limitation of use 1 3 the efficacy and safety of famciclovir tablets has not been established for patients 18 years of age immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in hiv infected patients black and african american patients with recurrent genital herpes herpes labialis cold sores genital herpes recurrent episodes suppressive therapy herpes zoster shingles recurrent orolabial or genital herpes the efficacy and safety of famciclovir tablets have not been established for patients 18 years of age patients with first episode of genital herpes patients with ophthalmic zoster immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in hiv infected patients black and african american patients with recurrent genital herpes" assertion.
- association label "relenza an influenza virus neuraminidase inhibitor nai is indicated for treatment of acute uncomplicated influenza type a and b infections 1 1 prophylaxis of influenza 1 2 important limitations of use not recommended for treatment or prophylaxis of influenza in 5 1 not proven effective for 1 3 1 3 not a substitute for annual influenza vaccination 1 3 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenza 1 3 relenza zanamivir inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza a and b virus in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days relenza is indicated for prophylaxis of influenza in adults and pediatric patients aged 5 years and older see warnings and precautions 5 1" assertion.
- association label "acitretin capsules usp are indicated for the treatment of severe psoriasis in adults because of significant adverse effects associated with its use acitretin capsules usp should be prescribed only by those knowledgeable in the systemic use of retinoids in females of reproductive potential acitretin capsules usp should be reserved for non pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments see boxed contraindications and warnings most patients experience relapse of psoriasis after discontinuing therapy subsequent courses when clinically indicated have produced efficacy results similar to the initial course of therapy" assertion.
- association label "captopril tablets usp are indicated for the treatment of hypertension hypertension in using captopril consideration should be given to the risk of neutropenia agranulocytosis see warnings captopril may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinations captopril is effective alone and in combination with other antihypertensive agents especially thiazide type diuretics the blood pressure lowering effects of captopril and thiazides are approximately additive captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatment heart failure captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 4 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients left ventricular dysfunction after myocardial infarction captopril tablets are indicated for the treatment of diabetic nephropathy proteinuria 5 mg day in patients with type i insulin dependent diabetes mellitus and retinopathy captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysis diabetic nephropathy in considering use of captopril tablets it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in non black patients see warnings angioedema" assertion.
- association label "prostin vr pediatric sterile solution is indicated for palliative not definitive therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival such congenital heart defects include pulmonary atresia pulmonary stenosis tricuspid atresia tetralogy of fallot interruption of the aortic arch coarctation of the aorta or transposition of the great vessels with or without other defects in infants with restricted pulmonary blood flow the increase in blood oxygenation is inversely proportional to pretreatment po 2 2 2 prostin vr pediatric should be administered only by trained personnel in facilities that provide pediatric intensive care" assertion.
- association label "to reduce the development of drug resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below rocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiae respiratory tract infections caused by lymphogranuloma venereum due to psittacosis ornithosis due to trachoma due to although the infectious agent is not always eliminated as judged by immunofluorescence inclusion conjunctivitis caused by nongonococcal urethritis in adults caused by or relapsing fever due to chancroid caused by plague due to tularemia due to cholera caused by campylobacter fetus infections caused by brucellosis due to species in conjunction with streptomycin bartonellosis due to granuloma inguinale caused by demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug species species respiratory tract infections caused by respiratory tract and urinary tract infections caused by species demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug upper respiratory infections caused by pneumoniae skin and skin structure infections caused by note tetracyclines including demeclocycline are not the drugs of choice in the treatment of any type of staphylococcal infection when penicillin is contraindicated tetracyclines including demeclocycline hydrochloride are alternative drugs in the treatment of the following infections uncomplicated urethritis in men due to and for the treatment of other uncomplicated gonococcal infections infections in women caused by syphilis caused by subspecies yaws caused by subspecies listeriosis due to anthrax due to vincent s infection caused by actinomycosis caused by clostridial diseases caused by species in acute intestinal amebiasis demeclocycline hydrochloride may be a useful adjunct to amebicides in severe acne demeclocycline hydrochloride may be a useful adjunctive therapy mycoplasma pneumoniae chlamydia trachomatis chlamydia psittaci chlamydia trachomatis chlamydia trachomatis ureaplasma urealyticum chlamydia trachomatis borrelia recurrentis haemophilus ducreyi yersinia pestis francisella tularensis vibrio cholerae campylobacter fetus brucella bartonella bacilliformis calymmatobacterium granulomatis escherichia coli enterobacter aerogenes shigella acinetobacter haemophilus influenzae klebsiella streptococcus staphylococcus aureus neisseria gonorrhoeae neisseria gonorrhoeae treponema pallidum pallidum treponema pallidum pertenue listeria monocytogenes bacillus anthracis fusobacterium fusiforme actinomyces israelii clostridium" assertion.
- obesity-with-metabolic-abnormality label "obesity with metabolic abnormality" assertion.
- nanopub label "add the URI of the nanopublication here" assertion.
- assertion label "Submitting a formalization paper to the Data Science special issue 2021" assertion.
- DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
- DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
- DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
- DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
- DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
- DataScienceSpecialIssue label "Formalization Papers Special Issue 2021 at Data Science" assertion.
- partOf label "is a part of" assertion.
- partOf label "is submitted as part of" assertion.
- partOf label "is submitted as part of" assertion.
- partOf label "is submitted as part of" assertion.
- partOf label "is submitted as part of" assertion.
- partOf label "is submitted as part of" assertion.
- partOf label "is submitted as part of" assertion.
- partOf label "is submitted as part of" assertion.
- partOf label "is submitted as part of" assertion.
- withStatus label "has the status" assertion.
- withStatus label "has the status" assertion.
- withStatus label "has the status" assertion.
- withStatus label "has the status" assertion.
- withStatus label "has the status" assertion.
- withStatus label "has the status" assertion.
- withStatus label "has the status" assertion.
- withStatus label "has the status" assertion.
- withStatus label "has the status" assertion.
- submitted label "submitted" assertion.